The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT ID: NCT00471003
Last Updated: 2010-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5448 participants
OBSERVATIONAL
2006-09-30
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
NCT01211171
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
NCT01392534
Pharmacovigilance and Patient Compliance in Hypertensive Patients
NCT02200575
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia
NCT01217879
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
NCT02176850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Pritor (Telmisartan , BAY68-9291)
Primary care hypertensive patients starting the therapy with Telmisartan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pritor (Telmisartan , BAY68-9291)
Primary care hypertensive patients starting the therapy with Telmisartan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Untreated or ineffectively treated arterial hypertension
Exclusion Criteria
* Allergy to telmisartan
* Pregnancy and lactation period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer Sp. z o.o
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Croatia
Many Locations, , Poland
Many Locations, , Slovakia
Many Locations, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KL0601PL
Identifier Type: -
Identifier Source: secondary_id
13929 - KL0601SI
Identifier Type: -
Identifier Source: secondary_id
12804 - KL0601SK
Identifier Type: -
Identifier Source: secondary_id
14326 - KL0601HR
Identifier Type: -
Identifier Source: secondary_id
12729
Identifier Type: -
Identifier Source: org_study_id
NCT00459095
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.